Harel Insurance Investments & Financial Services Ltd. Gamida Cell Ltd. Transaction History

Harel Insurance Investments & Financial Services Ltd.

$5.8 Billion
Q3 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 30, 2023	SELL	$0.85 - $1.87 $85 - $188	-101 Reduced 5.25%	1,822 $2,000
Q2 2023 Jul 17, 2023	SELL	$0.73 - $2.37 $310 - $1,009	-426 Reduced 18.14%	1,923 $4,000
Q1 2023 May 02, 2023	BUY	$0.68 - $1.71 $678 - $1,706	998 Added 73.87%	2,349 $2,000
Q4 2022 Jan 26, 2023	BUY	$1.15 - $2.1 $208 - $380	181 Added 15.47%	1,351 $2,000
Q3 2022 Oct 31, 2022	SELL	$1.53 - $3.39 $117 - $261	-77 Reduced 6.17%	1,170 $2,000
Q2 2022 Jul 19, 2022	SELL	$1.73 - $4.29 $98 - $244	-57 Reduced 4.37%	1,247 $2,000
Q1 2022 May 03, 2022	SELL	$2.22 - $4.47 $277 - $558	-125 Reduced 8.75%	1,304 $5,000
Q4 2021 Feb 07, 2022	BUY	$2.2 - $4.46 $3,143 - $6,373	1,429 New	1,429 $4,000

Others Institutions Holding GMDA

# of Institutions

Shares Held

2.2K

Call Options Held

Put Options Held

Ifp Advisors, Inc

2.2K
Shares

$66
0.0% of portfolio

View Full List

About Gamida Cell Ltd.

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

More about GMDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Harel Insurance Investments & Financial Services Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Harel Insurance Investments & Financial Services Ltd. with notifications on news.

Account